Boston Scientific Corp (BSX)vsGlobus Medical (GMED)
BSX
Boston Scientific Corp
$48.55
-0.34%
HEALTHCARE · Cap: $70.87B
GMED
Globus Medical
$80.00
0.00%
HEALTHCARE · Cap: $10.91B
Smart Verdict
WallStSmart Research — data-driven comparison
Boston Scientific Corp generates 565% more annual revenue ($20.61B vs $3.10B). GMED leads profitability with a 18.9% profit margin vs 17.3%. BSX appears more attractively valued with a PEG of 0.58. BSX earns a higher WallStSmart Score of 76/100 (B+).
BSX
Strong Buy76
out of 100
Grade: B+
GMED
Strong Buy74
out of 100
Grade: B
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-29.4%
Fair Value
$37.35
Current Price
$48.55
$11.20 premium
Margin of Safety
+36.4%
Fair Value
$138.77
Current Price
$80.00
$58.77 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Earnings expanding 100.0% YoY
Large-cap with strong market position
Growing faster than its price suggests
Reasonable price relative to book value
Strong operational efficiency at 20.6%
Earnings expanding 66.7% YoY
Conservative balance sheet, low leverage
Safe zone — low bankruptcy risk
Reasonable price relative to book value
Strong operational efficiency at 21.3%
Revenue surging 27.0% year-over-year
Areas to Watch
No major concerns identified
Expensive relative to growth rate
Comparative Analysis Report
WallStSmart ResearchBull Case : BSX
The strongest argument for BSX centers on EPS Growth, Market Cap, PEG Ratio. Profitability is solid with margins at 17.3% and operating margin at 20.6%. Revenue growth of 11.6% demonstrates continued momentum.
Bull Case : GMED
The strongest argument for GMED centers on EPS Growth, Debt/Equity, Altman Z-Score. Profitability is solid with margins at 18.9% and operating margin at 21.3%. Revenue growth of 27.0% demonstrates continued momentum.
Bear Case : BSX
No major red flags identified for BSX, but monitor valuation.
Bear Case : GMED
The primary concerns for GMED are PEG Ratio.
Key Dynamics to Monitor
BSX profiles as a mature stock while GMED is a growth play — different risk/reward profiles.
GMED carries more volatility with a beta of 0.95 — expect wider price swings.
GMED is growing revenue faster at 27.0% — sustainability is the question.
BSX generates stronger free cash flow (171M), providing more financial flexibility.
Bottom Line
BSX scores higher overall (76/100 vs 74/100), backed by strong 17.3% margins and 11.6% revenue growth. GMED offers better value entry with a 36.4% margin of safety. Both earn "Strong Buy" and "Strong Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Boston Scientific Corp
HEALTHCARE · MEDICAL DEVICES · USA
Boston Scientific Corporation, doing business as Boston Scientific, is a manufacturer of medical devices used in interventional medical specialties, including interventional radiology, interventional cardiology, peripheral interventions, neuromodulation, neurovascular intervention, electrophysiology, cardiac surgery, vascular surgery, endoscopy, oncology, urology and gynecology.
Globus Medical
HEALTHCARE · MEDICAL DEVICES · USA
Globus Medical, Inc., a medical device company, develops and markets healthcare solutions for patients with musculoskeletal disorders. The company is headquartered in Audubon, Pennsylvania.
Compare with Other MEDICAL DEVICES Stocks
Want to dig deeper into these stocks?